Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases,…
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union Pfizer Inc. and BioNTech SE announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active…
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development Merck known as MSD outside of the United States and Canada, announced early components of a multi-faceted strategy to provide rapid, broad and sustainable…
Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000 Immunomic Therapeutics, Inc. a clinical-stage biotechnology company and a U.S.-based subsidiary of HLB, announced that the first participant has been dosed in the Phase 1…
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 2026 Meiji Seika Pharma Co., Ltd. announced that results from the global Phase III…
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies Takeda announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and…
Tavoron Expands Automation Capabilities with Acquisition of Fluidraulics Tavoron, a national leader in industrial automation, robotics, compressed air, motion control and engineered solutions, announced the acquisition of Fluidraulics Inc., an automation component and system distributor that has served customers across…
Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches Charles River Laboratories International, Inc. announced a collaboration with Arovella Therapeutics Ltd a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS)…
Arima Genomics Announces Distribution Partnership with Active Motif for Research-Specific Hi-C Sequencing Kits and Services Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced a distribution partnership with…
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation…
Bayer Group to Consolidate U.S. Glyphosate Business Into a Distinct Entity Operating as Ruveon Bayer Group announced the consolidation of the U.S. glyphosate business into Ruveon LLC to optimize and align the business with the specific needs of the U.S.…
Pheno Therapeutics Granted FDA IND Clearance for Lead Multiple Sclerosis Therapeutic Candidate PTD802 Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced…